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Abstract
Background: Data on the potential efficacy of acupuncture (AC) in controlling intense or very intense pain in
patients with Herpes Zoster (HZ) has not been so far adequately assessed in comparison with standard
pharmacological treatment (ST) by a controlled trial design.
Methods: Within the VZV Pescara study, pain was assessed in HZ patients on a Visual Analogue Scale (VAS) and by
the McGill Pain Questionnaire (MPQ) both at the beginning and at the end of treatment. Response rates, mean
changes in pain intensity, differences in total pain burden with an area-under-the-curve (AUC) method over a
1-year follow-up and differences in the incidence of Post-Herpetic Neuralgia (PHN) were evaluated.
Results: One hundred and two patients were randomized to receive either AC (n = 52) or ST (n = 50) for 4 weeks.
Groups were comparable regarding age, sex, pain intensity at presentation and missed antiviral prescription. Both
interventions were largely effective. No significant differences were observed in response rates (81.6% vs 89.2%,
p = 0.8), mean reduction of VAS (4.1 +/- 2.3 vs 4.9 +/- 1.9, p = 0.12) and MPQ scores (1.3 +/- 0.9 vs 1.3 +/- 0.9,
p = 0.9), incidence of PHN after 3 months (48.4% vs 46.8%, p = 0.5), and mean AUC during follow-up (199 +/-
136 vs 173 +/- 141, p = 0.4). No serious treatment-related adverse event was observed in both groups.
Conclusions: This controlled and randomized trial provides the first evidence of a potential role of AC for the
treatment of acute herpetic pain.
Trial registration: ChiCTR-TRC-10001146.
Background
A significant proportion (18% to 41%) of patients suffering
with Herpes Zoster (HZ) experience intense or very
intense pain at presentation, frequently persisting after the
healing of rash [1-4]. Both pain in the acute phase and
chronic pain in post-herpetic neuralgia (PHN) may
severely impact on quality of life and health care costs,
interfering with physical, emotional and social functioning
of affected patients [5-7]. Therefore, several investigations
were carried out to identify effective strategies to control
Zoster-related pain [8-11].
Current therapeutic options include the repeated
administration of paracetamol and/or other NSAIDs for
the immediate relief of pain [9,10], antiviral drugs, which
accelerate the resolution of acute pain and may reduce
the incidence of PHN [12-14], long-term gabapentinoids
and local anaesthesia for selective nerve blockade in
patients with intense or very intense pain at presentation
[15-21]. Finally, opioid analgesics, including tramadol,
possibly combined with other neuroactive agents, such as
amitriptyline, have been used in the event of unrespon-
sive pain [22-26]. In the most suffering patients, however,
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administration of complex drug combinations, which
also bear the potential of relevant metabolic effects
[11,22].
In this context, the evidence that acupuncture may be
efficacious in the treatment of neuropathic pain syn-
dromes lead to the hypothesis of a potential beneficial
effect of this procedure for acute HZ-related pain
[27-29]. Therefore, several studies investigated the
impact of acupuncture in patients with intense pain due
to HZ or PHN, with controversial results [13,30-35].
None of them, however, was a randomized controlled
trial for acute pain in HZ [13,36,37].
Here we report on a randomized, controlled trial,
comparing the efficacy of acupuncture (AC) and stan-
dard pharmacological treatment (ST) in controlling
intense or very intense acute pain in patients with HZ.
Methods
Study design and population
The present randomized clinical trial was nested within
the “VZV Pescara Study”, a cohort study aimed at evalu-
ating the intensity of pain at presentation, pain persis-
tence, overall pain burden and relative predictors in HZ
patients [14]. Final approval of the study was granted by
the Ethical Committee of the Local Healthcare Agency
of Pescara in March, 2006. From May 2006 to April
2008, 41 General Practitioners (GPs) in the district of
Pescara, Italy, the Infectious Diseases (ID) Unit, the Der-
matology Unit, and Pain Management Clinic (PMC) of
the Pescara General Hospital asked all incident cases of
HZ to participate in the cohort study. All data were col-
lected by the Infectious Disease Unit using a specifically
created computerized network. All eligible patients
granting signed informed consent were followed for 12
months. Patients enrolled in the cohort study with pain
classified as intense or very intense on a five-degree
semi-quantitative scale (no pain, mild, moderate,
intense, very intense) were asked to participate in the
present trial. At enrolment, a second specific informed
consent was obtained, and the intensity of pain was re-
assessed using a Visual Analogue Scale (VAS) [38,39]. If
the intensity was ≥ 7 at VAS, participants were rando-
mized to receive either standard pharmacological treat-
ment (ST) or acupuncture (AC). The randomization
process was carried out by the Statistical Unit and strati-
fied by gender, age class (10 y) and pain intensity (VAS
7-8, and VAS 9-10). None of the investigators had any
role in the allocation of patients.
Intervention
In the AC arm, 8 sessions of Traditional Chinese Acu-
puncture were administered twice weekly by 2 experi-
enced acupuncture physicians, members of the Italian
School of Acupuncture and Traditional Chinese Medi-
cine, Boulogne, Italy. Acupuncture basic points used are
shown in Figure 1. In the ST arm, pregabalin was admi-
nistered to all patients. The initial dose of 75 mg/d was
gradually augmented based on patients’ needs (maximum
dose: 600 mg/daily, divided in 2 daily doses). In addition
to the gabapentinoid, in the ST arm local anaesthesia was
administered to all patientsu s i n g4 - 7m lo fc h i r o c a i n e
(1.5 mg/mL), either as intermittent peridural neural
blockade in those with lumbar or sacral localization, or
as intermittent perineural peripheral blockade in the
remaining cases. Local anaesthesia was repeated every
second day in patients complaining for yet uncontrolled
pain, up to 5 administrations. Finally, in the ST arm
transdermal buprenorphine (35-90 mcg/h) or oral oxyco-
done (50-400 mg daily) were prescribed to patients with
very intense or refractory pain. Dosages of opioids were
adjusted twice-weekly, in accordance with patients’ com-
plaints. Neither pregabalin, local anaesthesia nor opioids
were allowed at any time for patients in the AC group;
prescription of either drug was considered a protocol vio-
lation. For immediate pain relief, however, i.v. or oral
paracetamol (250 to 1000 mg in accordance to both body
weight and pain intensity) was allowed up to 3 times
daily in both study arms. The duration planned for both
treatments was 4 weeks.
Outcomes
The main outcome of the study was the reduction in
pain intensity between baseline and the end of the
4-week treatment, as measured by the reduction in
t h eV A Ss c o r e[ 3 8 , 3 9 ] .S e c o n d a r yo u t c o m e si n c l u d e d :
the reduction in the score of the McGill Pain Question-
naire (MPQ), which was administered by a psychologist
for the multidimensional definition of pain in the indivi-
dual patient [39-41]; the response rate (VAS score
decrease by at least 2 points during treatment); the
percentage of incident cases of PHN (defined as the pre-
sence of pain of any grade 3 months after enrolment -
data obtained from the nesting cohort study); the total
pain burden during the 12-month follow-up of the
cohort study; finally, the incidence of treatment-related
serious adverse events during treatment (grade 3 or
higher according to the WHO scale) [42]. The total pain
burden was quantified using an area-under-the-curve
(AUC) method [14,43]. In brief, all patients in the
cohort study were asked about pain severity at 1, 3, 6
and 12 months after enrolment, using the five-degree
semi-quantitative scale described above. To obtain the
AUC, measures of pain intensity were combined with
pain duration, and each patient’s AUC was calculated as
the sum of all areas obtained by multiplying the average
of 2 consecutive pain scores by the number of days
between the scores.
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Because of the recent debate on non-inferiority trials
[44], the study was conservatively planned with a super-
iority design. As mentioned above, the main outcome
was the difference in the mean change of VAS scores
from baseline to the end of the treatment between
groups. According to previous studies [30-35] and inclu-
sion criteria, the expected baseline mean VAS score was
8.0 ± 2.0 in both groups. The expected mean score at
the end of the follow-up was 2.5 ± 2.0 in the acupunc-
ture group; 4.0 ± 2.0 in the control group, with mean
changes from baseline of 5.5 (2.0) and 4.0 (2.0), respec-
tively. Using an unpaired t-test, and assuming an alpha-
error = 0.05 and an expected withdrawal/dropout rate
of 20%, a minimum of 34 subjects per group were
requested to achieve a 80% statistical power.
Data analysis
Kruskal-Wallis test was used to compare VAS, McGill
and AUC mean scores across groups at each time point,
as well as the mean change in each score during the fol-
low-up. Chi-squared test was used to compare the VAS
response rate and the prevalence of PHN between
groups. Within each group, the differences in VAS
and McGill scores between baseline and the end of the
4-week treatment were evaluated using paired t-test and
confirmed through the Wilcoxon matched-pairs signed
ranks test. A two-tailed p-value of 0.05 was considered
significant for all analyses, which were carried out using
Stata 10.1 (Stata Corp., College Station, TX, 2007).
Results
Characteristics of the sample
During the 2 years of enrolment in the VZV Pescara
cohort study, 451 patients were clinically and/or micro-
biologically diagnosed as HZ [14]. Of them, 129
reported intense or very intense pain at presentation
a n dw e r et h u se l i g i b l ef o rt h ep r e s e n tt r i a l .T w e n t y -
seven patients (21%) refused to participate, and 102
patients were randomized to receive either acupuncture
(AC, n = 52) or standard therapy (ST, n = 50) (Figure 2).
Many of the randomized patients, however, did not
receive the allocated intervention, because of rapid pain
quenching after enrolment (n = 13 in AC, n = 14 in ST),
or for consent withdrawal after randomization (n = 1 in
each group). Finally, 1 AC and 2 ST patients were lost to
follow-up, and 2 patients in each group underwent proto-
col violations (Figure 2). The final analyses were thus
based upon 34 patients in the AC group and 32 patients
in the ST group (Figure 2).
Figure 1 Relevant Acupoints used in patients treated with Acupuncture. (adapted from anatomic tables of Traditional Chinese Medicine,
Associazione Gruppo Studio “Società e Salute”, with permission).
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differences between groups were observed in mean age
(63.2 ± 16.1 y in ST; 64.2 ± 14.7 y in AC), male gender
(30.0% in ST and 35.5%, in AC), pain intensity at pre-
sentation (21.8% with very intense pain in ST; 23.6% in
AC) and missed antiviral prescription (10.0% in ST and
15.4% in AC). Similarly, as shown in Table 1, demo-
graphic and clinical characteristics of the 66 patients
entering the final analyses were well balanced between
groups. Finally, no differences were observed between
the 66 patients in the final sample and the 27 patients
refusing to participate (mean age 64.2 ± 16.0 y, males
18.5%, 17.4% with very intense pain). By contrast, and
expectedly, the 28 patients excluded after randomization
because of rapid pain reduction were significantly
younger (mean age 56.6 ± 19.8 y, p < 0.01) and with
less severe pain at presentation (7.1% with very intense
pain, p = 0.04).
Efficacy of acupuncture and standard analgesic therapy
As shown in Table 2, the 2 groups were also similar at
baseline as to the mean VAS and McGill scores (p =
0.6, p = 0.8, respectively). Both interventions were lar-
gely effective: the mean percentage of VAS score reduc-
tion from baseline to week 4 was of 51% in the ST
group (mean reduction in VAS score = 4.12 ± 2.3), and
62% in the AC group (mean reduction in VAS score =
4.85 ± 1.9); the mean percentage of McGill score reduc-
tion was 57% and 56%, respectively. Indeed, a highly sig-
nificant improvement from baseline to the end of the
follow-up was observed in each group for both pain
scores, and correspondent p-values were thus not
reported in the table (all p < 0.001).
Comparison between acupuncture and standard analgesic
therapy
No significant differences were observed between the 2
therapeutic approaches in any of the outcomes under
consideration (Table 2). Neither the mean reduction in
VAS score (p = 0.12) or in McGill score (p = 0.9), nor
t h er e s p o n s er a t e( p=0 . 8 ) ,n o rt h ei n c i d e n c eo fP H N
after 3 months (p = 0.5), nor the mean AUC (total pain
burden) during follow-up (p = 0.4) were significantly
different across groups.
As to safety, no serious adverse events (grade 3-4
according to WHO safety scale) related to both treat-
ments were observed in the 2 groups. In addition, none
of the patients were hospitalized or died during the 4
week treatment. Finally, none of them discontinued
Figure 2 Flow of participants through each stage of the trial.
Table 1 Demographic and clinical characteristics of
treated patients, by group
Characteristics Standard
Therapy
(n = 32)
Acupuncture
(n = 34)
p*
Male gender, % 40.6 32.3 0.5
Mean age in years (SD) 65.5 (12.8) 67.1 (12.8) 0.6
Current smoking, % 37.5 38.1 0.8
High-school or higher educational
level, %
28.1 35.3 0.5
Depression (clinical diagnosis), % 0.0 5.9 0.2
HIV-positive, % 0.0 0.0 0.9
Missed antiviral prescription, % 15.6 17.6 0.8
Very intense pain at
presentation, %
30.0 29.0 0.9
Vesicles (>50), % 35.0 48.4 0.3
Trauma at the site of VZV up to 6
m before onset, %
28.1 39.4 0.3
Surgical intervention at the site of
rash up to 6 months before
onset, %
59.4 55.9 0.8
Site of lesions
Facial 9.4 23.5 0.12
Cervical 6.3 8.8 0.7
Thoracic 53.1 44.1 0.5
Lumbar 31.2 23.5 0.8
Extension of lesions
Subdermatomerical 28.1 26.5 0.9
Dermatomerical 59.4 67.6 0.5
Multidermatomerical 12.5 5.9 0.3
Antiviral therapy
Acyclovir 40.6 32.4 0.5
Famcyclovir 0 5.9 0.2
Valacyclovir 31.3 29.4 0.9
Brivudin 9.4 11.8 0.8
Other antiviral 3.1 2.9 0.9
Missed antiviral prescription 15.6 17.6 0.8
* Fisher’s exact test for categorical variables, t-test for continuous variables
(age).
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dure-related discomfort.
Discussion
Lack of proper efficacy evaluations, adequate statistical
power and rational design of the previous studies asses-
sing the role of Acupuncture for Zoster related acute
pain is acknowledged [36,37]. Coghlan reported in 1992
the treatment of a small case series of patients with pain
caused either by acute HZ or by PHN, including 4
patients each. Electro-acupuncture alone was used and
reported as generally effective, endorsing the opportu-
nity for an exploratory trial [30]. More recently, Ni et al.
reported the treatment of 48 cases of HZ by nerve stem
puncturing. Among these, all of the 16 cases treated
within 1 week from pain onset were reported as cured,
in comparison with only 5 (15.6%) among the 32 cases
whose pain lasted over 1 week before treatment [33].
T h i ss t u d yw a sb a s e do nac o n s e c u t i v ec a s es e r i e sa n d
lacked of any control arm [33]. He et al. [32] described
60 cases of senile HZ treated by encircled acupuncture
plus valacyclovir (300 mg twice daily orally for 10 days)
versus valacyclovir only. The authors report that
patients were divided into 2 well balanced treatment
groups, not mentioning any randomization process; no
alternative analgesic treatment was administered to the
control group [32]. The only significantly different out-
come between groups was the duration of acute pain
(3.8 days for combined treatment vs 5.5 days for valacy-
clovir only); furthermore, a lower incidence of pain per-
sistence during follow-up was reported for patients
undergoing combined treatment (26.7 vs 53.3%),
although no definition was provided neither for PHN
nor for the duration of follow-up [32]. Therefore, to our
knowledge, this is the first randomized clinical trial asses-
sing the efficacy of acupuncture for the control of HZ-
related intense or very intense acute pain as well as for
the prevention of PHN during follow-up [30,32,33,36,37].
We found that both AC and ST, associated with the pre-
scription of antivirals, were efficacious in controlling
intense or very intense pain. Importantly, the degree of
pain control provided by AC was not significantly differ-
ent from that of ST.
Pain intensity was evaluated by the most frequently
used methods in VZV-related pain studies: VAS, to
obtain an easy quantification of pain intensity [38,39];
McGill Pain Questionnaire to qualifying pain [39-41].
We found no significant difference both in VAS and
McGill scores after 4 weeks of treatment between AC
and ST. Since pain intensity at rash onset is widely
reported as the best predictor of PHN [6,45-48], having
selected for patients with intense or very intense pain
we also evaluated the incidence of PHN at 3, 6 and 12
months after rash onset, as well as the total pain burden
during follow-up in the 2 study arms. Under the
assumption that acupuncture may have an immune
modulating activity [49-52], evaluating these endpoint
might have revealed an ability of this medical tool to
influence the rate of pain persistence and relapses. The
incidence of PHN at 3, 6 and 12 months, as well as the
mean AUC were overlapping in the 2 arms (Table 2).
The limited dimensions of our population do not allow,
however, to conclusively exclude, although unlikely, this
hypothesis.
I ts h o u l db en o t e dt h a tt h es t r a t i f i c a t i o nf o rp a i n
resulted in a perfect match of patients with very intense
pain at presentation, which could have otherwise
remarkably influenced the validity of our results for all
endpoints. Furthermore, the percentage of patients
which did not receive antiviral therapy was identical in
the 2 arms (15.6% and 17.6%, respectively), protecting
our trial from another possible confounding factor, that
Table 2 Comparison of the outcomes of treatments
under evaluation
Outcomes Standard
Therapy
(n = 32)
Acupuncture
(n = 34)
p*
Primary outcomes
VAS
Mean VAS score at baseline
(SD)
8.02 (1.69) 7.81 (1.48) 0.6
Mean VAS score after therapy
(SD)
3.89 (2.38) 2.96 (1.84) 0.08
Mean change in VAS score
(SD)
4.12 (2.29) 4.85 (1.87) 0.12
Response rate (>=2 VAS units
decrease), %
81.6 89.2 0.8
Secondary outcomes
McGill score
Mean McGill score at
baseline (SD)
2.32 (1.05) 2.38 (1.12) 0.8
Mean McGill score after
therapy (SD)
0.99 (0.69) 0.99 (0.73) 0.9
Mean change in McGill score
(SD)
1.32 (0.85) 1.33 (0.88) 0.9
Post-herpetic neuralgia at
3 months, %
48.4 46.8 0.9
Post-herpetic neuralgia at
6 months, %
33.3 29.0 0.7
Post-herpetic neuralgia at
12 months, %
10.3 3.6 0.3
Mean AUC during follow-up
(SD)
199(136) 173(141) 0.5
VAS = Visual Analogical Scale. AUC = Area under the curve (see text for
details).
* Kruskal-Wallis test was used to compare VAS, McGill and AUC mean scores
across groups at each time point, as well as the mean change in each score
during the follow-up. Chi-squared test was used to compare the VAS response
rate and the prevalence of PHN at each time point across groups. A paired t-
test was used to compare baseline vs end of therapy mean values of VAS and
McGill scores, within each group. All such differences were highly significant
(p < 0.001) and were thus omitted in the table to avoid redundancy.
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antiviral therapy between groups [1,53].
This study has some limitations, however, that must
be considered in interpreting results. First, we decided
to measure pain intensity both by VAS and McGill
scales at study entrance and after 4 weeks of treatment,
that is when the investigator felt that his intervention
for the control of acute pain was complete. Clearly, it
would have been interesting to measure ongoing pain
control at intermediate time points, to better appreciate
minor differences between the investigational arms. This
was not feasible, however, due to study budget con-
straints; in any case, most of the other investigations
assessing the efficacy of experimental treatments for
pain control were built with very similar or identical
designs [54,55].
Second, our trial was based upon a relatively small
sample of treated patients (n = 66). However, 41 GPs
and 3 hospital units were committed to recruit HZ
patients for 2 years, and more than 400 HZ patients had
to be enrolled to identify 129 patients with intense or
very intense pain at presentation (those with the highest
need of improvements in pain control). In addition, a
relatively large number of the eligible patients (n = 27)
refused to enter the trial. However, this was probably
unavoidable because of distrust or fear of an unusual
technique such as acupuncture. Notably, no differences
in age, gender and pain intensity were observed between
these patients and those included in our analyses.
Finally, 28 patients were excluded immediately after ran-
domization because of rapid pain reduction. However, it
would clearly have been unethical to enforce these
patients in a strong analgesic therapy as well as acu-
puncture. Notably, and expectedly, the latter patients
were younger and had very intense pain in only 2 cases.
This is the reason why it would have had very little
sense to use an intention-to-treat analysis, which is
usually the gold standard analysis for RCTs [56], in this
case. In other terms, the 28 patients with rapid pain
reduction represent a separate group of patients, not
needing long term analgesic therapy; they therefore may
not carry the potential for selection bias. As a final
remark on sample size, it should be noted that the
results of the 2 interventions were very similar and,
using a one-tailed non-inferiority approach, the statisti-
cal power of our analysis is acceptable for all outcomes,
ranging from a minimum of 81% for the change in VAS
score, up to 86% for the change in McGill score.
A third limitation is represented by the lack of both a
control arm with short acting analgesics only, and a
control arm with mock acupuncture [57-59]. This was
beyond our scope because of study budget constraints.
However, as the access to alternative drugs and comple-
mentary medicine techniques for acute pain control is
on the rise in our area and elsewhere in the world, we
felt that the design of this nested trial, investigating “real
life” differences in therapeutic potential between ST and
AC as presently used in severely ill HZ patients, might
still add to the knowledge on the analgesic efficacy of
acupuncture. Indeed, proper stratification of patients
between arms rather than blinding might have influ-
enced the assessment of the efficacy of either interven-
t i o n ,t h a ti st a k i n gi n t oa c c o u n t-w h e nd i s t r i b u t i n g
patients between arms - the main factors that may influ-
ence the efficacy of either intervention, such as age, pain
intensity and missed antiviral prescription. These vari-
ables were indeed well-matched in our study population.
A direct comparison between ST and AC for acute pain
in HZ is the object of another three-armed, partially
blinded randomized trial, known as ACUZoster, whose
design was recently published and which is still ongoing
[60].
Conclusions
With these caveats, our study provides the first evidence
from a randomized controlled design of a potential role
of acupuncture in the treatment of acute herpetic pain.
Patients with intense or very intense pain at presenta-
tion showed a significant and similar degree of pain
relief using acupuncture and standard pharmacological
therapy. Also, no differences between treatments were
observed in the incidence of severe adverse events.
Given that patients treated with acupuncture carry a
lower risk of cumulative drug toxicity, if these findings
will be confirmed by the ensuing ACUZoster trial and/
or by other investigations, acupuncture might be appro-
priately considered among the available therapeutic
options for the control of severe acute HZ related pain.
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